• Home
  • Signals
  • Screener
  • Heatmap
  • Recaps
  • News
  • Gurus
  • Politicians
Ryxel

    Command Palette

    Search for a command to run...

    healthcare News

    Categories

    • Market Analysis
    • Technology
    • Banking
    • Geopolitical
    • Stocks
    • Real Estate
    • Mergers & Acquisitions
    • Healthcare
    • FDA & Biotech
    • Economic Data
    • Energy
    • Sector Analysis
    • Earnings
    • Federal Reserve
    HCW Biologics Stock Soars on Cancer Immunotherapy Breakthrough
    Healthcare
    7mo ago

    HCW Biologics Stock Soars on Cancer Immunotherapy Breakthrough

    Shares surge over 85% after the company reveals a next-generation cancer drug that outperformed leading treatments in preclinical studies.

    AxoGen Nerve Graft Decision Pushed Back by FDA
    Healthcare
    7mo ago

    AxoGen Nerve Graft Decision Pushed Back by FDA

    Regulator extends review for Avance Nerve Graft to December after new manufacturing data requires more time for evaluation.

    Moderna Gains Canadian Approval For Updated COVID Vaccine
    Healthcare
    7mo ago

    Moderna Gains Canadian Approval For Updated COVID Vaccine

    Health Canada authorizes Spikevax targeting LP.8.1 variant, with all pre-filled syringe doses for 2025 to be produced domestically.

    Tharimmune Stock Surges Over 200% on Opioid Countermeasure Data
    Healthcare
    7mo ago

    Tharimmune Stock Surges Over 200% on Opioid Countermeasure Data

    Positive FDA feedback and promising 24-hour protection data for its fentanyl overdose prophylactic, TH104, fuel the rally.

    Iovance Soars as Melanoma Drug Gains First International Approval
    Healthcare
    7mo ago

    Iovance Soars as Melanoma Drug Gains First International Approval

    Health Canada's conditional nod for Amtagvi opens new markets for the cell therapy, following its earlier US FDA approval.

    Viking Therapeutics Plummets 43% Despite Positive Obesity Drug Data
    Healthcare
    7mo ago

    Viking Therapeutics Plummets 43% Despite Positive Obesity Drug Data

    Impressive Phase 2 trial results for its oral weight-loss pill were not enough to satisfy high investor expectations, triggering a massive sell-off.